Rosen Law Firm Encourages Sportradar Group AG Investors to Inquire About Securities Class Action Investigation - SRAD
NEW YORK, May 5, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announ…
prnewswire.com
FDMT(FDMT)
FDMT
Earnings in 1 day · May 7, 2026 · After close
Signal
Bullish Setup2↑
PRICE
Prev Close
9.44
Open
9.55
Day Range9.49 – 9.86
9.49
9.86
52W Range3.00 – 12.34
3.00
12.34
72% of range
VOLUME & SIZE
Avg Volume
627.1K
FUNDAMENTALS
P/E Ratio
-4.0x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.21
Market-like
Performance
1D
+2.86%5D
+10.34%1M
-2.31%3M
+15.73%6M↓
-7.61%YTD
+29.47%1Y↑
+171.99%Best: 1Y (+171.99%)Worst: 6M (-7.61%)
Quick Read
Trend—Insufficient MA data
Momentum
NEUTRAL
rev +230195% · -14% gross marginValuation
FAIR
P/E not availableHealth
MODERATE
CR 9.4 · FCF negativeLean Bullish
Key MetricsTTM
Market Cap$507.59M
Revenue TTM$85.21M
Net Income TTM-$140.11M
Free Cash Flow-$110.32M
Gross Margin-14.0%
Net Margin-164.4%
Operating Margin-187.2%
Return on Equity-31.7%
Return on Assets-24.7%
Debt / Equity0.04
Current Ratio9.39
EPS TTM$-2.42
Alpha SignalsView Intelligence →
Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
Health Radar
2 strong1 watch3 concern
39/100Liquidity
9.39Strong
Leverage
0.04Strong
Coverage
0.0xConcern
ROE
-31.7%Concern
ROIC
-30.2%Concern
Cash
$60MWatch
ANALYST COVERAGE14 analysts
BUY
▲ +239.9%upside to target
Stock Health
Composite Score
5 of 5 signals bullish
10/10
Technicals
●
✓RSI RangeRSI 52 — Bullish momentum
Volume
●
✓Volume FlowAccumulation — institutional buying
Fundamentals
●
✓Last EarningsBeat estimates
●
✓Analyst ConsensusBuy
●
✓LiquidityCurrent Ratio 9.39 — healthy liquidity
Upcoming Events
EEarnings ReportMay 7, 2026
Tomorrow
DEx-Dividend DateAug 4, 2026
In 90 days
PDividend PaymentSep 1, 2026
In 118 days
FinancialsFull statements →
Technicals
Technical SetupBEARISH
Technicals →Trend
→ PullbackGolden Cross · 50D leads 200D by 72.4%
-8.2% vs SMA 50 · +58.3% vs SMA 200
Momentum
RSI51.9Neutral territory
MACD-0.47Below zero — bearish pulse · compressing
Market Position
Price Levels
52W High
$12.34+27.1%
EMA 50
$9.91+2.1%
Current
$9.71
EMA 200
$6.13-36.8%
52W Low
$3.00-69.1%
52-Week RangeMid-range
$3.0072th %ile$12.34
Squeeze SetupVolume-based
Moderate Squeeze SetupAccumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.
20-Day Money Flow
Acc days:2
Dist days:1
Edge:+1 acc
Volume Context
Avg Vol (50D)421K
Recent Vol (5D)
304K-28%
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Earnings & Analysts
ANALYST ESTIMATES
Consensus of 7 analysts
Analyst revisions:EPS↑ Revised UpRevenue↑ Revised Up
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $33.5M $142319–$60.6M | — | -$3.26 | — | ±27% | High7 |
FY2026(current) | $8.8M $58225–$17.5M | ▼ -73.9% | -$3.83 | — | ±22% | High7 |
FY2027 | $13.2M $82806–$26.3M | ▲ +50.7% | -$3.85 | — | ±22% | High5 |
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryFDMT
Last 8Q
+20.0%avg beat
Beat 4 of 8 quartersMissed 4↓ Estimates falling+10%
Q2'24
+12%
Q3'24
-18%
Q4'24
-12%
Q1'25
-2%
Q2'25
-11%
Q3'25
+1%
Q4'25
+181%
Q1'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced heightAnalyst Activity
All ratings →No recent activity
Morgan StanleyUnderweight
Nov 7
UPGRADE
BMO CapitalOutperform → Market Perform
Jan 10
DOWNGRADE
Cantor FitzgeraldNeutral
Sep 23
DOWNGRADE
Leerink PartnersOutperform
Oct 18
UPGRADE
Goldman SachsBuy
Nov 15
UPGRADE
Insider Activity
SEC Filings →0 Buys/6 SellsNet Selling
Gupta AshooVP, Finance an…
$689
Mar 20
SELL
Gupta AshooVP, Finance an…
$3K
Mar 20
SELL
Gupta AshooVP, Finance an…
$686
Dec 20
SELL
Gupta AshooVP, Finance an…
$3K
Dec 20
SELL
Bizily ScottChief Legal Of…
$18K
Dec 16
SELL
Bizily ScottChief Legal Of…
$17K
Nov 17
SELL
Financials
INSTITUTIONAL OWNERSHIP
1
Nuveen, LLC
562K▲2
Peapod Lane Capital LLC
241K▼3
Perigon Wealth Management, LLC
146K▲4
Assenagon Asset Management S.A.
83K▼5
Simplify Asset Management Inc.
70K▲6
PROFUND ADVISORS LLC
32K▲7
COMMONWEALTH EQUITY SERVICES, LLC
28K▲8
Y-Intercept (Hong Kong) Ltd
25K▲News & Activity
FDMT News
20 articles · 4h ago
TrueBlue, Inc. (TBI) Q1 2026 Earnings Call Transcript
seekingalpha.com
DENTSPLY SIRONA Inc. (XRAY) Q1 2026 Earnings Call Transcript
seekingalpha.com
Energy Vault Holdings, Inc. (NRGV) Q1 2026 Earnings Call Transcript
seekingalpha.com
Blue Owl's Stack to consider $30 billion sale of Asia operations, Bloomberg News reports
reuters.com
LU Investors Have Opportunity to Lead Lufax Holding Ltd Securities Fraud Lawsuit First Filed by the Firm
prnewswire.com
Avalo Therapeutics Announces Pricing of $375 Million Public Offering
globenewswire.com
DoorDash: Clear Opportunity Ahead Of Q1 Results
seekingalpha.com
American Coastal Insurance Corporation (ACIC) Q1 2026 Earnings Call Transcript
seekingalpha.com
Veeco Instruments Inc. (VECO) Q1 2026 Earnings Call Transcript
seekingalpha.com
Myriad Genetics, Inc. (MYGN) Q1 2026 Earnings Call Transcript
seekingalpha.com
Microsoft's AI Engine Is Already Running Ahead
seekingalpha.com
Samsung hits $1 trillion: what's behind the 10% surge in one day?
invezz.com
Hercules Capital, Inc. (HTGC) Q1 2026 Earnings Call Transcript
seekingalpha.com
Entergy Corporation announces pricing of common stock offering with a forward component
prnewswire.com
Tempus AI, Inc. (TEM) Q1 2026 Earnings Call Transcript
seekingalpha.com
loanDepot, Inc. (LDI) Q1 2026 Earnings Call Transcript
seekingalpha.com
Workato Launches Otto, the Trusted AI Teammate that Gets Work Done
businesswire.com
Whitbread plc (WTBDY) Q4 2026 Earnings Call Transcript
seekingalpha.com
Lumentum Holdings Inc. (LITE) Q3 2026 Earnings Call Transcript
seekingalpha.com
About
4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP patients, 4D-110 is in a Phase 1 clinical trial for choroideremia patients and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease patients. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
Sector
Industry
Biological Product (except Diagnostic) Manufacturing
David H. KirnCo-Founder, President, CEO & Director
Kristian HumerCFO and Principal Financial & Accounting Officer
Peers— Health Care(7 companies)
Screen sector →| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
FDMT◀ | $9.71 | +2.86% | $508M | — | +23019459.5% | -16443.0% | 1500 |
| $68.78 | -0.30% | $13.3B | — | +12626.1% | -14525.8% | 1500 | |
| $89.52 | -1.81% | $11.7B | — | +3288.2% | -4239.0% | 1500 | |
| $502.47 | -3.12% | $11.5B | — | +43205.3% | -3008.0% | 1500 | |
| $223.06 | -0.29% | $11.4B | — | +6554.5% | -2868.8% | 1500 | |
| $74.93 | -1.91% | $10.5B | 51.9 | +2325815.3% | -19.7% | 1500 | |
| $175.95 | -3.34% | $10.3B | 28.0 | +1871.5% | 680.1% | 1500 | |
| Sector avg | — | -1.13% | — | 39.9 | +3630402.9% | -5774.9% | 1500 |